Nanostics Inc., a precision health company specializing in diagnostic tests developed with its ClarityDX® platform technology, has announced that the College of Physicians and Surgeons of Alberta (CPSA) has granted provisional accreditation to Nanostics Clinical Laboratory in Edmonton, Alberta, Canada.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, has unveiled new data showcasing the potent in vitro activity of NRX-101 (D-cycloserine + lurasidone) against reference strains of urinary tract pathogens known to cause complicated urinary tract infections (cUTIs)

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) has announced its receipt of Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for calcium gluconate in sodium chloride injection, specifically in 1000 mg/50 mL and 2000 mg/100 mL formulations. This injectable product is currently listed on the U.S. FDA shortage product list.

PsychoGenics Inc. (PsychoGenics) and Collaborations Pharmaceuticals, Inc. (CPI) are excited to announce the receipt of a $1 million Phase I Small Business Innovation Research (SBIR) grant. This grant represents a significant step forward in their collaboration, which seeks to utilize their combined AI capabilities to develop innovative drugs for mental health disorders.

XtalPi, a leader in AI-driven drug discovery, and Parthenon Therapeutics, a biotech firm focused on reshaping the tumor microenvironment, have announced a collaboration to develop new therapeutic antibodies for treating solid tumors.

Korean clinical trial sample analysis company, GCCL, announced on September 5th that it has implemented the Lab Information Management System (LIMS) for the first time in the sample analysis industry.

Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) have jointly announced the positive results from the Phase 3 innovaTV 301 global trial, which focused on recurrent or metastatic cervical cancer patients with disease progression after initial therapy.

INtRON Biotechnology, a biotech company, has announced a formal contract between its New Drug Part and the U.S. Army DEVCOM (U.S. Army Combat Capabilities Development Command) International Technology Center Indo-Pacific and Soldier Center. The contract aims to collaborate on the development of bacteriophages for combatting Uropathogenic Escherichia coli (UPEC) infections.

Amgen (NASDAQ: AMGN) and Horizon Therapeutics plc (NASDAQ: HZNP) have jointly announced the execution of a consent order agreement with the Federal Trade Commission (FTC) as a resolution to the ongoing FTC administrative lawsuit. This agreement paves the way for the final steps toward completing Amgen's acquisition of Horizon.

Pfizer has introduced cutting-edge cleanroom technology aimed at optimizing drug production efficiency in Tokyo.